Live attenuated chimeric yellow fever dengue type 2 (ChimeriVax™- DEN2) vaccine: Phase I clinical trial for safety and immunogenicity - Effect of yellow fever pre-immunity in induction of cross neutralizing antibody responses to all 4 dengue serotypes

• Main Authors: Farshad Guirakhoo, Scott Kitckener, Dennis Morrison, Remi Forrat, Karen McCarthy, Richard Nichols, Sutee Yoksan, Xiaochu Duan, Thomas H. Ermak, Niranjan Kanesa-Thasan, Philip Bedford, Jean Lang, Marie Jose Quentin-Millet, Thomas P. Monath
• Other Authors: Acambis
• Format: Article
• Published: 2018
• Subjects: Immunology and Microbiology; Pharmacology, Toxicology and Pharmaceutics
• Online Access: https://repository.li.mahidol.ac.th/handle/123456789/23377
• Institution: Mahidol University

A randomized double-blind Phase I Trial was conducted to evaluate safety, tolerability, and immunogenicity of a yellow fever (YF)-dengue 2 (DEN2) chimera (ChimeriVax™-DEN2) in comparison to that of YF vaccine (YF-VAX®). Forty-two healthy YF naïve adults randomly received a single dose of either Chim...